Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy

Tang, Wenjiao; Xu, Yangfan; Xiang, Bing

doi:10.1007/s00277-020-04244-7

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case series, osseous involvement was very common in AMM patients. It is also interesting to note that in the literature reviews, 18 of the cases presented with extramedullary plasmacytoma (34.6%) located in the right brachial plexus [4], pancreatic involvement [5], brain [8], soft tissue [18], intraperitoneal mass [11], liver [19], and left parotid region [23], etc. Extramedullary plasmacytoma (EMP) is typically seen in MM patients at disease relapse or as an aggressive disease presentation.…”

Section: Discussionmentioning

confidence: 99%

“…It is also interesting to note that thrombocytopenia was in the initial presentation in 9.6% of patients. Eighteen cases (34.6%) presented with extramedullary plasmacytoma involving right brachial plexus [4], pancreatic involvement [5], brain [8], soft tissue [18], intraperitoneal mass [11], liver [19], and left parotid region [23], etc. IgA was the most common M protein subtype (32.7%) and 1q amplification was the most prevalent cytogenic abnormality (23%).…”

Section: Cases Presentation Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Anaplastic Multiple Myeloma: Case Series and Literature Review

Chu

Chase

et al. 2022

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

Background: Anaplastic multiple myeloma (AMM) is a very rare but distinct subtype of multiple myeloma (MM) with an extremely poor prognosis. Due to its rarity, AMM lacks detailed descriptions and clear definitions. Moreover, there is no consensus on the treatment and evidence suggests that AMM responds poorly to several novel therapies. We conducted a literature review and retrospective case series to determine clinical characteristics, pathological features, and outcomes of AMM. Case Presentation: Published case reports and case series of AMM since 1983 were systematically extracted and reviewed. A total of 52 patients with AMM were reported in the PUBMED since 1983, including 26 males (50%) and 26 females (50%). The age ranged from 29 years old to 85 years old, with a mean age of 57.02 years old. Most of the patients presented with bone pain (23, 44.2%), fatigue (18, 34.6%), plasmacytoma (18, 34.6%) and weight loss (7, 13.5%). The median survival of the patients was 4 months. To investigate the outcomes of patients with AMM in the current era of treatment, a series of 14 patients with AMM diagnosed at our institute between December 2012 and July 2021was retrospectively analyzed. Our retrospective case series consisted of 12 males (85.7%) and 2 females (14.3%), with a mean age of 59 years old. Most of our AMM patients displayed bone lytic lesions as a common manifestation. The common cytogenetic abnormality was 1q amplification. All patients received standard combination chemotherapy consisting of proteasome inhibitors and/or immunomodulatory agents, and half of the patients underwent autologous hematopoietic stem cell transplantation. The median progression-free survival (PFS) and overall survival (OS) for our 14 AMM patients were 0.84 years and 1.52 years, respectively, which was significantly worse than the regular MM patients treated at our institute from 2003-2013 who had a PFS of 2.28 years and OS of 4.92 years. Conclusions: AMM is a very rare, morphologically distinct variant of MM. It has adverse cytogenetics and an aggressive course. It is often resistant to standard chemotherapy and presents with an extremely low survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Cases Presentation Literature Reviewmentioning

confidence: 99%

Anaplastic Multiple Myeloma: Case Series and Literature Review

Chu

Chase

et al. 2022

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

show abstract

“…A part of relapsed/refractory myeloma can progress into such an aggressive variant. Only few de novo AMM cases have been reported in recent years [2] , [3] , [4] , and their clinicopathological features are yet to be elucidated. Here, we report a case of de novo AMM harboring the rearrangement of MYC oncogene, which was successfully treated with conventional chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Anaplastic multiple myeloma with MYC rearrangement

Ichikawa

Fukuhara

Hashimoto

et al. 2022

Leukemia Research Reports

View full text Add to dashboard Cite

A 52-year-old man with rapidly progressive paraplegia was presented to us with paravertebral tumors. Laminectomy with tumor resection was performed, and pathological analysis of the tumor revealed compact proliferation of anaplastic plasmacytoid cells. G-band analysis of the tumor revealed a complex karyotype, including IgH/MYC translocation. The patient was diagnosed with anaplastic multiple myeloma (AMM) with MYC arrangement, and cytotoxic chemotherapy followed by autologous hematopoietic stem cell transplantation resulted in long-term disease-free remission. This is the first report describing a case of de novo AMM with MYC rearrangement, suggesting that conventional chemotherapy could be a treatment option for this formidable disease.

show abstract

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy

Cited by 2 publications

References 9 publications

Anaplastic Multiple Myeloma: Case Series and Literature Review

Anaplastic Multiple Myeloma: Case Series and Literature Review

Anaplastic multiple myeloma with MYC rearrangement

Contact Info

Product

Resources

About